Navigation Links
Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration
Date:2/10/2010

PLANTATION, Fla. and DALLAS, Feb. 10 /PRNewswire/ -- Goodwin Biotechnology Inc., a full service Contract Biomanufacturing Company and Macrocyclics, Inc., a manufacturer of customized chelating agents, jointly announced today their collaborative agreement on Chelation and Bioconjugation.  The collaboration will strengthen joint customer projects in Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing.

"Clinical development programs in nuclear medicine with biotargeted agents require combining chelation chemistry and bioconjugation chemistry to create a product," said Garry E. Kiefer, Ph.D., Chief Executive Officer at Macrocyclics.   "In Goodwin Bio, we found a perfect collaborator to jointly advance diagnostic and therapeutic medicine."

"We are excited about collaborating with Macrocyclics, a company dedicated to the leading-edge development of new chelation chemistry platforms," said Muctarr Sesay, Ph.D., Vice President of Process Development at Goodwin Bio.  "Our integrated cGMP services combined with Macrocyclics' chelation expertise will enhance clinical development programs in nuclear medicine."

About Goodwin Biotechnology, Inc.

Goodwin Bio, (GBI) located in Plantation, FL., is a full service contract biomanufacturing company and specializes in process development and cGMP production of protein based therapeutics for pre-clinical and early phase clinical trials. The products manufactured by Goodwin Bio are being used in clinical trials and the Company has assisted in the preparation of several IND filings for various clients.  GBI caters small to midsize biotech companies, universities, cancer research institutes and various branches of the U.S. Government.

About Macrocyclics, Inc:

Macrocyclics, (Macrocyclics, Inc.) located in Dallas, TX., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. A broad library of catalog products designed to meet the needs of basic and applied research customers as well as custom cGMP products and services to accelerate clinical development programs are provided.  Clients are international and include government agencies, scientific investigators, biotech and pharmaceutical companies.

SOURCE Goodwin Biotechnology Inc.


'/>"/>
SOURCE Goodwin Biotechnology Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
3. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
6. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
7. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the ... major shareholders, Clean Technology Fund I, LP and Clean ... based venture capital funds which together hold approximately ... fully diluted, as converted basis), that they have entered ... equity holdings in Biorem to TUS Holdings Co. Ltd. ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):